As 2026 unfolds, the landscape of cardiovascular medication safety is shifting under the weight of new FDA recalls and updated prescribing information. From carcinogenic impurities in losartan to ...
Thousands of bottles of a prescription medicine for treating high blood pressure and congestive heart failure have been recalled over the detection of trace amounts of a possible carcinogen. About ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results